Alvogen

What Alvogen does

Alvogen is a US-based pharmaceutical company that develops, in-licenses, manufactures, and markets generic, branded, and injectable pharmaceutical products. Founded in 2009 by Róbert Wessman and headquartered in Morristown, New Jersey, the company operates three core subsidiaries: Alvogen Generics (over 50 marketed products across solid oral dose, modified-release tablets, transdermal patches, soft gelatin capsules, creams, ointments, and inhalation products), Almatica Pharma (a CNS-focused branded business spanning pain, anti-infective, cardiovascular, and psychiatry therapies), and Almaject (generic injectables for acute and alternate-site healthcare markets). Manufacturing is anchored at the wholly-owned Norwich Pharmaceuticals facility in Norwich, New York, a 350,000+ square-foot plant on 400 acres with capacity of 3.5 billion tablets, drawing on a 130+ year heritage of US pharmaceutical manufacturing.

Alvogen pursues a vertical integration strategy centered on difficult-to-make generics — including complex inhalation, long-acting injectables, peptides, transdermal patches, controlled-release formulations, and 505(b)(2) brand products — supported by R&D operations in Pine Brook, NJ, and a biosimilars partnership with Alvotech. The commercial model relies on a dedicated US salesforce, authorized wholesaler and distributor networks, and GPO relationships to reach hospitals, retail and specialty pharmacies, long-term care facilities, clinics, and physician offices. Revenue is generated through one-time product sales at competitive generic price points (average copay ~$6, offering up to 85% savings versus branded alternatives), supplemented by licensing and milestone payments such as the Solaxa agreement for SLX-100.

In December 2025, Alvogen was acquired by Taiwan-based Lotus Pharmaceutical Co., Ltd. (TWSE: 1795) for US$658 million, becoming a controlled subsidiary with access to commercial reach across Asia, Europe, Japan, China, and Brazil. The transaction followed a $669 million debt refinancing in March 2025 and a $100 million growth investment from Aztiq Pharma Partners in June 2021. New leadership was installed in January 2026, with Divya Patel as CEO and Tunie Zaku promoted to Chief Operating Officer. The company employs 500+ FTEs in the US (headcount band 1,001-5,000) and reported $150 million invested in US development and manufacturing sites. Revenue is not publicly disclosed.

Name

Alvogen

Legal name

Alvogen, Inc.

Website

https://alvogen.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Alvogen is a US-based pharmaceutical company that develops, manufactures, and markets complex generic, branded, and injectable pharmaceutical products across multiple therapeutic areas, serving hospitals, pharmacies, and healthcare providers via dedicated US sales and wholesale channels.

Ownership category

akta.pro rank

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals Sales: Sale of generic pharmaceutical products across solid oral dose, modified release, transdermals, creams, ointments, and injectables. The company has over 50 products currently on market with an extensive R&D pipeline fueling growth. Revenue is generated through direct sales to wholesalers and pharmacies, with pricing based on competitive generic market dynamics.
2. Branded Pharmaceuticals (Almatica): Almatica Pharma acquires, develops, and commercializes brand named Rx products including pain, anti-infective, cardiovascular, and psychiatry therapies. Revenue generated through branded pharmaceutical sales at higher price points than generics.
3. Generic Injectables (Almaject): Almaject commercializes generic injectable pharmaceuticals for acute and alternate site healthcare markets. Revenue from sale of injectable products including Buprenorphine/Naloxone sublingual film, Dexrazoxane, Metoprolol Tartrate Injection, and Temsirolimus Injection.
4. Licensing and Milestone Payments: Alvogen receives upfront payments, development and regulatory milestone payments, and double-digit royalties on net sales from licensing arrangements. The Solaxa agreement provides up to $95 million in aggregate milestone payments plus royalties on SLX-100 global sales.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Alvogen develops, manufactures, and markets generic and branded pharmaceutical products in the United States. The portfolio includes complex generics (transdermal patches, modified-release tablets, soft gelatin capsules), sterile injectables via the Almaject subsidiary, and branded CNS/pain/anti-infective/cardiovascular products via the Almatica subsidiary. The company operates an in-house manufacturing facility in Norwich, New York with 3.5 billion tablet capacity across 78 SKUs and 26 molecules, supporting over 50 commercialized products.

Product overview

Alvogen is a US-based pharmaceutical company focused on developing, in-licensing, manufacturing, and marketing generic and branded pharmaceutical products. The company operates through three main subsidiaries: Alvogen (Generics) offering over 50 generic products including complex formulations like transdermal patches, modified-release tablets, and inhalation products; Almatica Pharma for CNS-focused branded products including pain, anti-infective, cardiovascular, and psychiatry therapies; and Almaject for injectable pharmaceuticals serving acute and alternate site healthcare markets. The portfolio spans multiple therapeutic areas (oncology, cardiology, respiratory, neurology, gastroenterology) and includes complex generics, 505(b)(2) brand products, and a biosimilar partnership with Alvotech. Alvogen maintains in-house manufacturing capabilities at its Norwich, New York facility and was acquired by Lotus Pharmaceutical Co., Ltd. in December 2025.

Differentiator

Problem solved

Functional benefit

Brands

• Almatica Pharma: Focused on acquisition, development and commercialization of brand named Rx products including pain, anti-infective, cardiovascular and psychiatry related therapies.
• Almaject

Products and services

• Alvogen Generics Core generic pharmaceutical portfolio spanning solid oral dose, modified-release tablets, soft gelatin capsules, powders, oral suspensions, transdermal patches, creams, and ointments. Over 50 products currently on market addressing oncology, cardiology, respiratory, neurology, and gastroenterology therapeutic areas. Sold to wholesalers, pharmacies, hospitals, and GPOs in the United States.
• Almatica Pharma (Branded CNS)

Quantifiable outcome

• Generic medications save patients up to 85% compared to branded alternatives, with average copay of approximately $6 versus over $50 for brand-name drugs

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• Solaxa Inc.coreStrategic or Co-development Partner · 23 February 2026Alvogen entered a global license agreement with Solaxa for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B). Alvogen acquires worldwide rights and will commercialize SLX-100 globally including through its Almatica CNS label in the US. Solaxa receives upfront payment, development/regulatory/sales milestone payments totaling up to $95 million in aggregate, plus double-digit royalties on net sales.
• Lotus Pharmaceutical Co., Ltd.flagshipStrategic or Co-development Partner · 23 September 2025Lotus Pharmaceutical (TWSE: 1795) completed acquisition of Alvogen Pharma US parent company in December 2025 for US$658 million. Transaction gives Lotus access to US platform including dedicated salesforce, in-house US manufacturing at Norwich NY facility, and complementary R&D pipeline. Alvogen is now a controlled subsidiary of Lotus. The deal builds on existing long-standing collaboration between the two companies.
• MIT (Massachusetts Institute of Technology)minorStrategic or Co-development Partner · 1 January 2011Alvogen teamed up with MIT through its Industrial Liaison Program (ILP), the industry's chief gateway to MIT resources. With nearly 200 leading companies as members, the program provides Alvogen access to extensive expertise and represents an educational and collaborative platform.
• AlvotechcoreStrategic or Co-development PartnerAlvogen has partnered with Alvotech (Iceland-based fully integrated specialty biopharmaceutical company focused on biosimilar development and manufacturing) to provide biosimilar medicines to the US market. Alvotech specializes in biopharmaceutical product creation from cell line development to commercial manufacturing.
• Columbia UniversityminorStrategic or Co-development PartnerAlvogen is an official sponsor of Columbia University's Life Course Project (Longitudinal Investigation for Epigenetic Causes and Outcomes in Urban and Rural Social Environments), a unique research project designed to better understand biological, behavioral, and environmental factors influencing healthy development of young people. Alvogen works with distinguished scientists representing different academic disciplines.
• White & Case LLPminorImplementation/ SI/ Consulting PartnerWhite & Case LLP acted as legal advisor to Alvogen on the sale to Lotus Pharmaceutical Co., Ltd.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Sandoz: Recently spun off Novartis generics business with significant US generics, biosimilars, and injectable footprint; competes across the same hospital, retail, and specialty channels as Alvogen at global scale.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with overlapping US generics, injectables, and CNS specialty portfolio; broader scale and pipeline make it a broad incumbent benchmark rather than a direct niche competitor.

Others

• Alvotech: Icelandic biosimilar-focused biopharmaceutical company that is both a partner (via biosimilar co-commercialization agreement) and founder-affiliated entity with Róbert Wessman as chairman; comparable through its complex biologics manufacturing focus.

Direct peers

• Mallinckrodt Pharmaceuticals: Specialty generics and branded pharmaceutical company with overlapping portfolios in CNS, pain, and hospital-administered products, providing a directly comparable US specialty generics platform.
• Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with a comparable portfolio of complex generics, injectables, and specialty branded products serving similar retail, hospital, and institutional channels.
• Aurobindo Pharma USA: US subsidiary of Indian generic manufacturer with broad US generics portfolio across therapeutic areas directly overlapping Alvogen's solid oral, injectable, and complex generic offerings.
• Hikma Pharmaceuticals: US-focused specialty generics and injectable manufacturer with comparable hospital-channel reach, injectable portfolio, and complex generics strategy; one of the closest comparables to Alvogen's Almaject platform.
• Lannett Company: US generic pharmaceutical manufacturer with a portfolio overlapping Alvogen's solid oral dose and specialty generics across similar distribution channels to wholesalers, GPOs, and retail pharmacies.
• Apotex: Canadian-based generic pharmaceutical manufacturer with significant US presence, comparable generic portfolio of small-molecule solid oral and injectable products sold through similar channels.
• Endo International: Specialty and generics pharmaceutical company with parallel exposure to sterile injectables, generics, and CNS/pain branded products through comparable distribution to hospitals, GPOs, and retail pharmacies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/alvogenpr
• Facebookfacebook.com/alvogen-986212954844908
• LinkedInlinkedin.com/company/alvogenpr

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvogen